For Investors

• Analyst Coverage
• Annual Reports
• Calendar
• Contact Investor Relations
• Financial Reports
• Frequently Asked Questions
• Information Circular
• Management and Investor Relations
• Media Coverage
• News Releases
• Presentations
• Request Documents
• SEDAR Filings
• Stock Quote
• Webcasts
• Why Invest?
  • Corporate Overview
  • Milestones
  • Partnerships
  • Patents

News Releases ::

• Isotechnika Pharma and 3SBio Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
  More...August 24, 2010
  
• Isotechnika reports second quarter 2010 financial results
  More...August 11, 2010
  
• Lux Biosciences receives Complete Response letter from FDA for voclosporin
  More...August 4, 2010
  

Media Coverage ::

• Pharma Watch: 3SBio, Isotechnika Partner on Voclosporin
  More...August 25, 2010
• Isotechnika lands China deal
  More...August 25, 2010
• Isotechnika Pharma signs $6m commercialization agreement for transplant organ rejection drug with 3SBio in China
  More...August 24, 2010

Events ::

• Annual & Special Meeting
  More...September 9, 2010

Patents

Isotechnika currently has been issued 184 patents related to voclosporin and has 56 patents pending related to this compound. These patents cover synthesis, composition of matter, method of use and formulation. Isotechnika has been issued 27 patents related to its TAFA93 compound with an additional 8 patents pending.